Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we talk radiopharmaceuticals, GLP-1s, psychedelics, cardiomyopathy and more.
The need-to-know this morning
- Syndax Pharmaceuticals won FDA approval for Revuforj, a new treatment for a genetically defined type of advanced leukemia.
- Cybin said its drug based on psilocin, a psychedelic found in certain types of mushrooms, alleviated depressive symptoms in a mid-stage clinical trial.
- Neurogene discontinued further development of a high dose of its gene therapy for Rett syndrome after a patient reported a potentially life-threatening side effect.
New Zepbound data gives insights on hospitalizations but not much on deaths
From STAT’s Elaine Chen: Over the weekend at the American Heart Association meeting in Chicago, researchers presented full results of a trial testing Eli Lilly’s obesity drug Zepbound in patients with heart failure with reduced ejection fraction, or HFpEF. Lilly had previously announced topline results that Zepbound reduced the risk of major problems (heart failure-related urgent visits or hospitalizations, intensification of diuretic treatment, or cardiovascular deaths) — by 38% compared to placebo.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in